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ABSTRACT
Introduction Multimorbidity has increased globally 
over the past two decades, due to ageing populations 
and increased burden of non- communicable diseases 
(NCDs). In a country like South Africa, with a growing 
burden of NCDs and a high prevalence of HIV, information 
on multimorbidity can improve planning for healthcare 
delivery and utilisation, and reduce costs in the context 
of constrained health resources. This review aims to 
synthesise prevalence studies on multimorbidity, and 
identify dominant clusters and trends of multimorbidity in 
South Africa.
Methods and analysis We will search electronic 
bibliographic databases (PubMed, Scopus, JSTOR, 
POPLINE, PsycINFO, ScienceDirect, Web of Science and 
CINAHL), and the reference lists of included articles. Two 
researchers will independently screen title and abstracts, 
and then full text to identify studies published before 
and in 2020 that report on prevalence of multimorbidity 
in South Africa. Risk of bias assessments will be 
done for each study. Information on the prevalence of 
multimorbidity and disease clusters will be extracted 
from each study. Where possible, prevalence of specific 
clusters of multimorbidity will be pooled using a random 
effects meta- analysis to account for variability between 
studies. The I2 statistic will be used to establish the extent 
of heterogeneity due to variation in prevalence estimates 
rather than due to chance. The systematic review will be 
reported according to the Preferred Reporting Items for 
Systematic reviews and Meta- Analyses.
Ethics and dissemination Only published journal articles 
will be included in the systematic review. This review 
received ethics approval as part of a larger project by 
the University of the Western Cape Biomedical Science 
Research Ethics Committee (BM20/5/8). The findings from 
this research will be used to estimate the prevalence of 
multimorbidity in South Africa and will contribute to the 
design of future research projects. The findings will be 
disseminated in a peer- reviewed journal article.
PROSPERO registration number CRD42020196895.
INTRODUCTION
Multimorbidity, defined as the coexistence of 
two or more chronic conditions, has increased 
globally in the past two decades.1 2 Although 
a gold standard definition of multimor-
bidity has not been established, it has been 
recommended that the operationalisation of 
multimorbidity can include a combination of 
non- communicable diseases (NCDs), mental 
health conditions and infectious diseases.1 
The increase in multimorbidity is attributed 
to ageing populations3 and the growing 
burden of NCDs.1 Whereas the increase in 
NCDs was initially predominantly observed in 
high- income countries; recently this increase 
was also reported in low and middle- income 
countries (LMICs).4
The prevalence of multimorbidity places 
additional stress on already severely strained 
health systems in LMICs5 by driving up 
healthcare utilisation and costs.6–9 Further-
more, multimorbidity alters the patterns of 
individual health behaviours and access of 
health services; which in turn, has further 
implications for health systems responsive-
ness and pressing the urgency for further 
health reforms away from a programmatic 
approach to comprehensive, integrated 
services delivery. The need for reforms to 
integrate the treatment of various chronic 
conditions has been acknowledged.10 11 
Researchers have since highlighted the need 
to incorporate elements specific to people 
living with multimorbidity. These include the 
need for: multimorbid patients to have access 
to coordinated and multidisciplinary teams 
of health professionals; support for patients 
to self- manage their workload, and evidence- 
based guidelines applicable to multimorbid 
Strengths and limitations of this study
 ► To our knowledge, this will be the first systematic 
review to estimate the prevalence of multimorbidity 
in South Africa.
 ► This systematic review will include articles conduct-
ed in community/general and health- facility settings.
 ► This protocol follows the Preferred Reporting Items 
for Systematic reviews and Meta- Analyses Protocols 
201535 guidelines.
 ► The findings will be used to inform future research 
projects and can guide health policy and planning 
for service delivery in South Africa.
 ► The study may be limited by the way in which source 
articles define multimorbidity. P
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conditions.12–15 It is essential to grasp the magnitude and 
clustering of multimorbidity to inform health policy and 
regulations at a national level.
South Africa has a quadruple burden of disease of HIV/
AIDS, NCDs, injuries and other communicable diseases 
with perinatal conditions, maternal causes and nutri-
tional deficiencies.16 17 As HIV treatment has improved, 
people living with HIV in South Africa can expect a near- 
normal life expectancy.18 However, ageing adults living 
with HIV are at a higher risk of developing chronic condi-
tions such as NCDs compared with those not infected, 
and at an earlier age.19 An emerging pattern of HIV and 
NCD multimorbidity was described in the country.13 The 
burden of mental health conditions in people living with 
HIV has also been recognised20–23; with an estimated 40% 
of people living with HIV also afflicted by a diagnosable 
mental disorder.24 25 This demonstrates the complex 
burden of disease in the country.
Systematic reviews on multimorbidity that were 
conducted to date were mostly on older adults and in 
high- income countries.26–30 These reviews reported 
pooled prevalences of multimorbidity between 38% and 
66%.26 28 31 In contrast, only two reviews included or were 
conducted on multimorbidity in LMICs.32 The ‘global’ 
systematic review included LMICs but limited the included 
studies to community settings; and did not include health-
care settings.31 Although the systematic review of multi-
morbidity in India and Bangladesh included primary 
healthcare settings, none were selected.33 The authors 
acknowledged that this was due to a gap in the multimor-
bidity literature in primary healthcare settings.
While community- based studies on multimorbidity 
are important, it is also essential for reviews on multi-
morbidity to include studies conducted in healthcare 
settings, because these studies can give a good indica-
tion of the number of people accessing healthcare for 
chronic conditions.29 Both community- based and health 
facility- based studies provide insight into the scale of the 
problem. To our knowledge, no study has been done to 
assess the prevalence of multimorbidity in South Africa 
that included studies in primary care settings. There is a 
need for research into multimorbidity in LMICs on the 
African continent as their disease burden differs from 
high income countries; that is, overlapping burdens 
of NCDs and infectious diseases which lead to new 
multimorbidity disease combinations.19 The proposed 
systematic review aims to synthesise existing literature 
on the prevalence of multimorbidity in South Africa, 
and identify common disease clusters and trends in the 
country.
Research questions
This systematic review aims to address the following 
review questions:
1. What is the prevalence of multimorbidity in persons 
over the age of 18 years in South Africa in studies re-
ported up to and including 2020?
2. What is the prevalence of multimorbidity in adult 
males and females stratified by age group in South Af-
rica in studies reported up to and including 2020?
3. What are common multimorbidity disease clusters in 
South Africa in studies reported up to and including 
2020?
4. What are the trends in the prevalence of multimorbid-
ity disease clusters in South Africa over time?
METHODS AND ANALYSIS
Protocol and registration
The methods for this systematic review was developed 
in accordance with the Preferred Reporting Items for 
Systematic Reviews and Meta- Analyses (PRISMA)34 and 
the PRISMA Protocols statement (online supplemental 
appendix 1).35 The systematic review is registered with the 
International Prospective Register of Systematic Reviews.
Eligibility criteria
The Condition, Context and Population (CoCoPop) 
mnemonic for prevalence systematic reviews36 will be 
used to define the inclusion criteria (table 1).
Condition
Articles about the prevalence of multimorbidity in South 
Africa will be included. Case definitions for multimor-
bidity may be defined in various ways. Ideally, articles will 
need to provide a clear description and definition of how 
they have conceptualised multimorbidity. For articles 
where multimorbidity has not been clearly defined, this 
article will adopt an operational definition of multimor-
bidity, similar to Pati, Swain.33 Their operational defini-
tion states ‘studies documenting two or more chronic 

























will also be assessed 
to determine if they 
fit the definition of 
multimorbidity.
Study types include 
population- based 
studies and cross- 
sectional studies.
  Study settings include 
ambulatory, community- 
based, general practice, 
primary healthcare 
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conditions, even though not mentioning the term multi-
morbidity’.34[p.4] The article will also need to be explicit 
about which diseases have been included in their defini-
tion of multimorbidity.
The way in which multimorbidity was measured will 
need to be clearly defined. For example, whether a count 
of conditions was done. Also, the way in which diseases 
were diagnosed must be clear (eg, self- report, clinical 
assessment, laboratory test).
Context
Articles must report on studies conducted in South 
Africa. The setting of the study can be community- based, 
or health facility- based (eg, inpatient and outpatient).
Population/types of participants
This systematic review will be restricted to people who 
reside in South Africa and are over the age of 18 years 
old. Ideally, articles should report on the prevalence of 
multimorbidity by age group and sex.
Outcomes
The primary outcome will be the prevalence of multimor-
bidity in South Africa.
Types of studies
Observational, cross- sectional study designs are the most 
appropriate for determining the prevalence of a health 
condition, particularly common conditions of long dura-
tion.36 Thus, included articles will be cross- sectional or 
population- based study designs.
Articles must document the prevalence of multimor-
bidities, or their data must allow for the calculation of 
multimorbidity prevalence. Articles will need to define 
multimorbidity as the coexistence of at least two disease 
conditions or an operational definition will be applied. 
Articles with a sample size of less than 100 participants 
will be excluded as these studies may be susceptible to the 
influence of extreme observations.37 All articles before 
and including 2020 will be included. Additionally, in 
order to be included in this study, articles must be orig-
inal and peer reviewed.
Inclusion and exclusion criteria are described in 
table 2. The following types of documents or studies will 
be excluded:
 ► Reviews, opinion pieces, conference presenta-
tions, letters, editorials, dissertations, abstracts, grey 
literature.
 ► Studies not conducted in South Africa.
 ► Studies that do not allow for the calculation of multi-
morbidity prevalence.
 ► Experimental studies.
 ► Studies not published in English.
Search strategy
A comprehensive search strategy was formulated by 
reviewing search terms used in other systematic reviews 
of multimorbidity.26–31 33 38–41 The search strategy will be 
modified, where necessary, according to the database or 
search engine used (table 3). Reference lists of included 
articles will be screened for relevant articles. The following 
electronic databases will be searched: PubMed, Scopus, 
JSTOR, POPLINE, PsycINFO, ScienceDirect, Web of 
Science and CINAHL.
Search terms will include ‘multimorbidity’ and linguistic 
variations such as ‘multi- morbidity’, ‘multimorbidities’, 
‘multi- morbidities’, ‘multi morbidity’, ‘multi morbid-
ities’, multiple morbidities’, ‘multiple- morbidities’. 
Terms such as ‘multiple conditions’, ‘multiple diseases’, 
‘multiple chronic diseases’, ‘multiple chronic condi-
tions’, ‘multiple illnesses’, ‘multiple diagnoses’, ‘multi- 
pathology’, ‘chronic condition’, ‘chronic diseases’33 will 
also be included. These terms will be further restricted by 
location ‘South Africa’ and by method and study design 
‘prevalence, epidemiology, pattern’. This will be done 
by using the ‘AND’ and ‘OR’ Boolean operators where 
appropriate.
The term ‘comorbidity’ is now accepted to be distinct 
from multimorbidity.40 This study will exclude the search 
term ‘comorbidity’ as was done by another multimor-
bidity systematic review.31 However, if the search results 
include comorbidity studies that examine the prevalence 
of multimorbidity, the eligibility of these studies will be 
considered.
Study selection and eligibility criteria
One reviewer will conduct the literature search. Once the 
search is run, citations will be downloaded into a refer-
ence management system such as EndNote (EndNote 
X8, Thomson Reuters). Duplicates will be excluded using 
the EndNote deduplication function. Citations will be 
exported from EndNote into Rayyan.42
Selection process
Two reviewers (RAR and EBT) will independently screen 
the titles and abstracts of the search output to select poten-
tially eligible studies using prespecified eligibility criteria. 
The web- based system, Rayyan, will be used to manage 
the screening process. Rayyan was designed by the Qatar 
Table 2 Summary of inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Peer- reviewed articles. Non peer- reviewed articles and 
grey literature.
Articles with more than 
100 participants.
Articles with smaller sample 
sizes (<100 participants).
Articles about 
multimorbidity in adults in 
South Africa.
Articles not about 
multimorbidity, not about adults 
or not conducted in South 
Africa.
Observational studies. Experimental studies.
Articles where it is 
possible to calculate 
the prevalence of 
multimorbidity.
Articles where it is not possible 
to calculate the prevalence 
of multimorbidity or to only 
calculate multimorbidity in a 
subset of people with a disease.
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Foundation to expedite systematic reviews by semiauto-
mating the initial screening of titles and abstracts.42 The 
full- text of potentially relevant articles will be retrieved 
and independently reviewed by two review authors (RAR 
and EBT) for eligibility.
Eligible citations will be uploaded into a web- based 
electronic system, the Burden of Disease Review Manager 
(BODRevMAN). This system was designed by the Burden 
of Disease Research Unit of the South African Medical 
Research Council to facilitate, systemise and manage the 
process of systematic review, the risk of bias assessment 
and provide a summary of data extracted.37 BODRevMAN 
is tailored to the systematic review of observational 
studies. It facilitates the independent quality assessment 
and extraction of information from included full- text arti-
cles. Any disagreements will be resolved through discus-
sion or another review author (VP- vW or BvW) will add 
input to enable a consensus. A PRISMA flow diagram will 
detail the study selection decisions made.
The researchers will not be blinded to the authors, 
titles and institutions of potentially eligible studies. 
Where there are multiple studies from the same dataset, 
the most appropriate data will be included. Where addi-
tional information is needed, the authors of the study will 
be contacted. One reviewer will email the corresponding 
author and a maximum of two attempts will be made, 
separated by one week.
Quality assessment
Two reviewers will independently assess study characteris-
tics and the risk of bias of each study. The reviewers will 
use a modified checklist43 based on the Hoy et al44 risk of 
bias tool for population- based prevalence studies and the 
Newcastle- Ottawa Scale45 for assessing the quality of non- 
randomised studies (online supplemental appendix 2). 
The tool has been described previously.37 46 Results from 
the two researchers will be compared and differences 
will be discussed between them. Where consensus is not 
reached, a third reviewer (VP- vW) will be called on to 
arbitrate. Studies with a high risk of bias will be excluded 
and the reasons for their exclusion will be noted.
Data extraction
Two reviewers will independently extract data using 
BODRevMAN. The data extraction facilitated by 
BODRevMAN is in accordance with recommendations 
by Munn et al36 for prevalence systematic reviews. The 
following data will be extracted:
 ► Citation details: authors, title, journal and year.
 ► Study details: study design, study setting (commu-
nity or health facility), timeframe for data collection, 
geographical location and sample size.
 ► Case definition: how multimorbidity was defined and 
how disease conditions were measured.
 ► Participant characteristics: age, sex, urban/rural, soci-
oeconomic characteristics.
 ► Description of main results: percentage prevalence 
of multimorbidity (n/N) and 95% CIs. Prevalence of 
conditions stratified by age and sex. Information on 
the most common disease clusters in the study sample.
In addition, the aims of the study, the method of data 
analysis used and any points of difference that may affect 
the interpretation of findings36 will be noted.
Data synthesis
The results will be presented in accordance with the 
PRISMA statement. Studies that are deemed to have a 
moderate or low risk of bias will be included in the anal-
ysis. Where appropriate, graphs will be used to display 
the information from included articles. The quantitative 
results will be summarised for individual studies and will 
include point estimates and interval estimates (eg, 95% 
CIs). The prevalence data will be broken down by age, 
sex and disease clusters if the information is available. 
Differences and similarities between studies will be docu-
mented. Possible trends will also be noted.
If articles are amenable to meta- analysis, this will be 
done using Stata V.15 (College Station, Texas). A random 
effects meta- analysis will be used. Estimates will be pooled 
to obtain a summary estimate and 95% CI. A χ2 test will be 
used to assess statistical heterogeneity and the I2 statistic 
will be used to assess the degree of homogeneity.47 48 
Where there are more than ten studies, publication bias 
will be assessed with a funnel plot and an egger test.49
Where sufficient data exist, subgroup analysis will 
be conducted based on multimorbidity case definition 
used, study setting (eg, community or health facility), 
age groups, sex and time periods. Ideally, multimorbidity 
prevalence will be estimated by age group and sex.
If it is not possible to do a meta- analysis, the findings 
from included articles will be presented in summary tables 
that will include the year of data collection, the study type 
and setting (community or health facility- based), location 
of study, the definition of multimorbidity used in each 
study, the diseases and number of diseases included in 
the study and how they were ascertained (eg, measured 
or self- reported).
Patient and public involvement
No patients will be involved directly in this study.
Table 3 Example search strategy for PubMed
Search Query
#4 Search ((#3 NOT (animals(mh] NOT humans(mh))))
#3 Search (#1 AND #2)
#2 Search (South Africa(mh] OR South Africa*(tiab] 
OR RSA [tiab] OR Africa, Southern(mh:noexp)OR 
Southern Africa(tiab))
#1 Search (Multimorbidity OR multi- morbidity 
OR multimorbidity(tiab] OR “multi morbidities” 
OR multimorbidity(mh] OR multimorbidit* OR 
multimorbid OR multimorbidities OR multi- 
morbidit* OR “multiple morbidities” OR “multiple- 
morbidit*” OR multidisease* OR multi- disease* OR 
“multiple disorder” OR “multiple illness”
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ETHICS AND DISSEMINATION
This systematic review will be the first to review all avail-
able studies reporting on the prevalence of multimor-
bidity in South Africa. This study will provide estimates 
that will be valuable to health services planning. It will 
also provide much needed information on multimor-
bidity on the African continent and in LMICs in general.
The findings from this systematic review will be written 
up using the PRISMA guidelines. It will be disseminated 
through publication in a peer- reviewed journal article 
and/or conference proceedings.
This study is a secondary analysis of published studies. 
The data from published studies cannot be linked to 
individuals. This review received ethics approval as part 
of a larger project by the University of the Western 
Cape Biomedical Science Research Ethics Committee 
(BM20/5/8).
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